Genmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly.The company's top line is currently dominated by royalties...
Source LinkGenmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly.The company's top line is currently dominated by royalties...
Source Link
Comments